ResultsIQ

ResultsIQ › Latest results › Apollo Hospitals Enterprise Limited

Apollo Hospitals Enterprise Limited strategy deck summary

NSE: APOLLOHOSP · BSE: 508869

Strategy deck of 30 Jun 2025, summarised by AI from the filing.

AHL acquired 11.2% stake in Keimed in March 2025, ahead of the plan, after completing Advent Tranche 2 in March 2025.

Key takeaways

  1. Change AHL acquired 11.2% stake in Keimed in March 2025, ahead of the plan, after completing Advent Tranche 2 in March 2025.

Original filing on BSE

Apollo Hospitals Enterprise Limited Q1 FY27 results

As filed: Revenue ₹7,044 cr (+21% year on year), EBITDA ₹1,092 cr (+28% year on year), PAT ₹610 cr (+38% year on year), EBITDA margin 15.5% (+92 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹6,606 cr (+18% year on year), EBITDA ₹1,011 cr (+31% year on year), PAT ₹551 cr (+33% year on year), EBITDA margin 15.3% (+154 bps). Score 67 of 100, Above trend. Revenue and EBITDA growth were above the company's own trend; profit growth was well below it. EBITDA margin rose 154 bps year on year. Revenue rose ₹1,014 cr on a year ago, more than the ₹648 cr it added the year before. Share price after the results: +5.1% in 30 days (Nifty 500: +2.5%).
  • Q3 FY26: Revenue ₹6,477 cr (+17% year on year), EBITDA ₹965 cr (+27% year on year), PAT ₹516 cr (+36% year on year), EBITDA margin 14.9% (+112 bps). Score 62 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA growth was in line with it; profit growth was well below it. EBITDA margin rose 112 bps year on year. Profit lagged EBITDA because of depreciation, interest or other income, not the business. Revenue rose ₹950 cr on a year ago, more than the ₹676 cr it added the year before. Share price after the results: +4.9% in 30 days (Nifty 500: −7.8%).
  • Q2 FY26: Revenue ₹6,304 cr (+13% year on year), EBITDA ₹941 cr (+15% year on year), PAT ₹494 cr (+25% year on year), EBITDA margin 14.9% (+31 bps). Score 38 of 100, Below trend. Revenue growth was below the company's own trend; EBITDA and profit growth were well below it. EBITDA margin rose 31 bps year on year. Revenue rose ₹715 cr on a year ago, against ₹742 cr the year before. Share price after the results: −7.6% in 29 days (Nifty 500: +1.4%).
  • Q1 FY26: Revenue ₹5,842 cr (+15% year on year), EBITDA ₹852 cr (+26% year on year), PAT ₹441 cr (+40% year on year), EBITDA margin 14.6% (+131 bps). Score 52 of 100, In line with trend. Revenue and EBITDA growth were in line with the company's own trend; profit growth was well below it. EBITDA margin rose 131 bps year on year. Revenue rose ₹756 cr on a year ago, more than the ₹668 cr it added the year before. Share price after the results: +8.9% in 30 days (Nifty 500: +2.4%).
  • Q4 FY25: Revenue ₹5,592 cr (+13% year on year), EBITDA ₹770 cr (+20% year on year), PAT ₹415 cr (+61% year on year), EBITDA margin 13.8% (+80 bps). Score 51 of 100, In line with trend. Revenue growth was below the company's own trend; EBITDA growth was well below it; profit growth was in line with it. EBITDA margin rose 80 bps year on year. Revenue rose ₹648 cr on a year ago, more than the ₹642 cr it added the year before. Share price after the results: +6.2% in 28 days (Nifty 500: +3.6%).
  • Q3 FY25: Revenue ₹5,527 cr (+14% year on year), EBITDA ₹762 cr (+24% year on year), PAT ₹379 cr (+49% year on year), EBITDA margin 13.8% (+113 bps). Score 60 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA growth was below it; profit growth was well below it. EBITDA margin rose 113 bps year on year. Profit fell 4% from last quarter. Revenue rose ₹676 cr on a year ago, more than the ₹587 cr it added the year before.
  • Q2 FY25: Revenue ₹5,589 cr (+15% year on year), EBITDA ₹817 cr (+30% year on year), PAT ₹396 cr (+59% year on year), EBITDA margin 14.6% (+168 bps). Score 77 of 100, Above trend. EBITDA margin rose 168 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Apollo Hospitals Enterprise Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.